Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

PHASE3CompletedINTERVENTIONAL
Enrollment

496

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

January 18, 2024

Study Completion Date

November 7, 2024

Conditions
Migraine
Interventions
DRUG

Rimegepant

Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12

DRUG

Placebo

Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12

Trial Locations (44)

790-0925

Medical Corporation Seikokai Takanoko Hospital, Matsuyama

816-0802

Jinnouchi Neurosurgical Clinic, Kasuga-shi

816-0824

Ikeda Neurosurgical Clinic, Kasuga-shi

373-8585

SUBARU Health Insurance Society Ota Memorial Hospital, Ota-shi

730-0031

Doi Clinic Internal Medicine/Neurology, Hiroshima

070-8530

Japanese Red Cross Asahikawa Hospital, Asahikawa-shi

060-8570

Nakamura Memorial Hospital, Chūōku

003-0003

Higashi Sapporo Neurology and Neurosurgery Clinic, Sapporo

658-0064

Konan Medical Center, Higashinada-ku

663-8014

Nishinomiya Munic. Ctr. Hosp., Nishinomiya-shi

310-0015

Mito Kyodo General Hospital, Mito

929-0342

Kijima Neurosurgery Clinic, Kahoku-gun

020-8505

Iwate Medical University Uchimaru Medical Center, Morioka

892-0842

Atsuchi Neurosurgery Hospital, Kagoshima

892-0844

Tanaka Neurosurgical Clinic, Kagoshima

216-8511

St. Marianna Univ. Hospital, Kawasaki-shi

211-8588

Fujitsu Clinic, Nakahara

780-0051

Atago Hospital, Kochi

780-8011

Umenotsuji Clinic, Kochi

861- 4193

Saiseikai Kumamoto Hospital, Kumamoto

600-8811

Tatsuoka Neurology Clinic, Kyoto

982-0014

Sendai Headache and Neurology Clinic, Medical Corporation, Sendai

870-0831

Ooba Clinic for Neurosurgery & Headache, Ōita

700-0964

Makabe Clinic, Okayama

700-8557

Okayama City General Medical Center Okayama City Hospital, Okayama

530-8480

Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka

556-0015

Tominaga Clinic, Osaka

589-8511

Kindai University Hospital, Osakasayama-shi

560-0012

Takase Intern. Med. Clinic, Toyonaka-shi

350-0495

Saitama Medical University Hospital, Iruma-gun

338-8577

Saitama Neuropsychiatric Institute, Saitama-shi

420-0853

Japanese Red Cross Shizuoka Hospital, Shizuoka

321-0293

Dokkyo Medical Univ. Hosp., Shimotsuga-gun

113-8431

Juntendo University Hospital, Bunkyo-ku

192-0032

Tokai univ. hachioji hosp., Hachioji-shi

108-0075

Shinagawa Strings Clinic, Minato-ku

108-8642

Kitasato University Kitasato Institute Hospital, Minato-ku

156-0043

USUDA CLINIC for internal medicine, Setagaya-ku

160-0017

Fukuuchi Pain Clinic, Shinjuku-ku

160-8582

Keio University Hospital, Shinjuku-ku

167-0054

Nishiogi Pain Clinic, Suginami-ku

930-0803

Sakura Neuro Clinic, Toyama

747-0802

Nagamitsu Clinic, Hofu-shi

400-0124

Nagaseki Headache Clinic, Kai-shi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05399485 - Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) | Biotech Hunter | Biotech Hunter